Global Information
회사소개 | 문의 | 비교리스트

세계의 폰다파리눅스(Fondaparinux) 시장(2020-2026년)

Global Fondaparinux Market 2020-2026

리서치사 Orion Market Research Pvt Ltd
발행일 2020년 06월 상품 코드 949665
페이지 정보 영문
가격
US $ 3,600 ₩ 4,268,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 5,691,000 Printable PDF (Enterprise License)


세계의 폰다파리눅스(Fondaparinux) 시장(2020-2026년) Global Fondaparinux Market 2020-2026
발행일 : 2020년 06월 페이지 정보 : 영문

혈전증을 예방하는 항응고제 폰다파리눅스(Fondaparinux) 시장은 예측기간 중 대폭적인 성장을 나타낼 것으로 예측됩니다. 심부정맥혈전증(DVT) 유병률 대폭적 확대, 고령자 인구 증가 등의 요인이 시장 성장을 추진하고 있습니다. 노년 인구 증가는 골다공증 유병률 증가의 주요 원인의 하나이며, 고관절 및 슬관절 치환술 수요가 증가하는 요인이기도 합니다. 인공 고관절 치환 수술, 고관절 골절, 슬관절 수술을 포함한 하지 정형외과 수술을 받는 환자에게는 정맥혈전색전성 이벤트(VTE)를 막기 위해 폰다파리눅스 투여를 합니다. 2019년 지역별 점유율에서는 고관절 및 슬관절 치환술 증가에 의해 북미 지역이 큰 점유율을 차지할 것으로 예측됩니다.

세계의 폰다파리눅스(Fondaparinux) 시장을 조사했으며, 시장 정의와 개요, 시장 성장에 대한 각종 영향요인 분석, 관련 규제, 시장 규모 추정과 예측, 제품 종류 등 각종 세분화별 내역, 지역·주요 국가별 상세 분석, 경쟁 상황, 기업 점유율, 주요 기업 개요 등을 정리했습니다.

제1장 보고서 개요

제2장 시장 개요와 인사이트

  • 조사 범위
  • 애널리스트의 견해·현재 시장 동향
  • 규제

제3장 경쟁 상황

  • 기업 점유율 분석
  • 주요 전략 분석
  • 주요 기업 분석

제4장 시장 영향요인

  • 성장 촉진요인
  • 성장 억제요인
  • 시장 기회

제5장 시장 분석과 예측 : 각종 부문별

  • 제품 종류별
    • 브랜드 의약품
    • 제네릭 의약품

제6장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 스페인
    • 프랑스
    • 기타
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 기타
  • 기타 지역

제7장 기업 개요

  • Apicore LLC
  • Aurobindo Pharma Ltd.
  • Cadila Healthcare Ltd.(CHL)
  • Dr Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • Italfarmaco S.p.A.
  • Mylan N.V.
  • Sandoz International GmbH
  • ScinoPharm Taiwan, Ltd.
KSM 20.07.30

LIST OF TABLES

  • 1. GLOBAL FONDAPARINUX MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
  • 2. GLOBAL BRANDED FONDAPARINUX DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL GENERICS FONDAPARINUX DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL FONDAPARINUX MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 5. NORTH AMERICAN FONDAPARINUX MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 6. NORTH AMERICAN FONDAPARINUX MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
  • 7. EUROPEAN FONDAPARINUX MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 8. EUROPEAN FONDAPARINUX MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
  • 9. ASIA-PACIFIC FONDAPARINUX MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 10. ASIA-PACIFIC FONDAPARINUX MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
  • 11. REST OF THE WORLD FONDAPARINUX MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL FONDAPARINUX MARKET SHARE BY PRODUCT TYPE, 2019 VS 2026 (%)
  • 2. GLOBAL FONDAPARINUX MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 3. US FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 4. CANADA FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. UK FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. FRANCE FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. GERMANY FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. ITALY FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. SPAIN FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. ROE FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. INDIA FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. CHINA FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. JAPAN FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. REST OF ASIA-PACIFIC FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF THE WORLD FONDAPARINUX MARKET SIZE, 2019-2026 ($ MILLION)

Global Fondaparinux Market Size, Share & Trends Analysis Report, By Product Type (Branded and Generics) and Forecast, 2020-2026

The global fondaparinux market is estimated to grow significantly during the forecast period. The major factors contributing to the market growth include a significant rise in the prevalence of deep vein thrombosis (DVT) and rising geriatric population. As per the United Nations (UN), by 2050, 1 in 6 people globally will be more than the age of 65, increased from 1 in 11 in 2019. In 2019, 703 million people were aged 65 years or over globally, which is expected to double to 1.5 billion in 2050. Increasing geriatric population is one of the major causes for an increase prevalence of osteoporosis, which results in the emerging demand for hip and knee replacement procedures. This contributes to the rising adoption of fondaparinux to prevent venous thromboembolic events (VTE) in patients who are undergoing orthopedic surgeries of the lower limbs including hip replacement surgery, hip fracture, and knee surgery. Fondaparinux works by blocking the activity of some clotting substances in the blood. It is being significantly used owing to the longer half-life and high efficiency than heparin.

Geographically, the market is classified into North America, Europe, Asia-Pacific, and Rest of the World (RoW). In 2019, North America is expected to hold a significant share in the market owing to the rising number of hip and knee replacement procedures in the region. In 2015, 57,673 hip primary replacement were performed by 2,572 surgeons in the US and 87,593 primary knee replacement procedures were performed by 2,281 surgeons in the country. These procedures are rising significantly owing to the rising prevalence of orthopedic conditions in the country, which in turn, contributes to the adoption of fondaparinux to prevent blood clot after the hip and knee replacement procedure.

Some key players in the market include Mylan N.V., GlaxoSmithKline plc, Dr. Reddy's Laboratories, Inc., Aurobindo Pharma Ltd., and Cadila Healthcare Ltd. (CHL). The strategies adopted by the market player include mergers and acquisitions and product launches to expand market share and gain a competitive advantage. For instance, in December 2017, Aurobindo Pharma Ltd. gained the US FDA approval for production and marketing of its generic version of Fondaparinux sodium injection, 2.5mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL, and 10 mg/0.8 mL single-dose prefilled syringes, for the prevention of DVT. The approved ANDA is a therapeutically equivalent and bioequivalent to the reference listed drug (RLD) product Arixtra Injection of Mylan Ireland. The product was introduced in January 2018.

Research Methodology

The market study of the global fondaparinux market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Fondaparinux Market Research and Analysis by Product Type

The Report Covers:

  • Comprehensive research methodology of the global fondaparinux market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global fondaparinux market.
  • Insights about market determinants, which are stimulating the global fondaparinux market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. Stakeholders

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules and Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Mylan N.V.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. GlaxoSmithKline plc
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Dr. Reddy's Laboratories, Inc.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Aurobindo Pharma Ltd.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Cadila Healthcare Ltd. (CHL)
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Fondaparinux Market by Product Type
    • 5.1.1. Branded
    • 5.1.2. Generics

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Apicore LLC
  • 7.2. Aurobindo Pharma Ltd.
  • 7.3. Cadila Healthcare Ltd. (CHL)
  • 7.4. Dr Reddy's Laboratories Ltd.
  • 7.5. GlaxoSmithKline plc
  • 7.6. Italfarmaco S.p.A.
  • 7.7. Mylan N.V.
  • 7.8. Sandoz International GmbH
  • 7.9. ScinoPharm Taiwan, Ltd.
Back to Top
전화 문의
F A Q